Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Atea Completes Phase 3 Enrollment for Hepatitis C Treatment
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, announced completion of enrollment of more than 880 treatment-naïve patients in the C-BEYOND Phase 3 trial evaluating the fixed-dose combination (FDC) regimen of bemnifosbuvir and ruzasvir compared to the FDC regimen of sofosbuvir and velpatasvir for the treatment of hepatitis C virus (HCV). C-BEYOND is being conducted at approximately 120 clinical trial sites in the US and Canada. Phase 3 topline results are expected mid-year 2026.
Samsung Biologics Acquires Human Genome Sciences from GSK
Samsung Biologics a leading contract development and manufacturing organization (CDMO), announced that its wholly owned U.S. subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK . This strategic move secures Samsung Biologics’ first U.S.-based manufacturing site, a significant expansion of the company’s global footprint and its long-term commitment to the U.S. market.
Swisslog Healthcare Appoints Maria Garces as Vice President of Product Management
Swisslog Healthcare, a leading supplier of transport and pharmacy automation solutions, announces the appointment of Maria Garces as Vice President of Product Management. Garces brings deep experience in global product management, strategy, and business development across healthcare and technology sectors. In her new role, Garces will lead product management initiatives, develop strategic roadmaps, and drive innovation across Swisslog Healthcare’s portfolio of solutions.
Datma and Rhythm Biosciences Partner on Genomic Data Collaboration
Datma, a leader in federated real-world data access, and Rhythm Biosciences Ltd, a developer of predictive cancer diagnostics including its geneType risk assessment portfolio, announced a new collaboration to explore how datma. FED, Datma’s federated data platform, could support and accelerate the development and commercialization of Rhythm’s genomic-integrated cancer risk prediction tools.
Bristol Myers Squibb Partners with U.S. to Boost Drug Access
Bristol Myers Squibb, has reached an agreement with the U.S. government to provide Eliquis, a widely used oral anticoagulant, to the Medicaid program at no cost and to donate over seven tons of Eliquis active pharmaceutical ingredient to strengthen the U.S. supply chain. This initiative reflects BMS’s ongoing commitment to cardiovascular health, improving patient outcomes, and collaborating with policymakers to lower healthcare costs while maintaining support for future innovation.
To share your insights, please write to us at sudipto@intentamplify.com
